I'm LongbridgeAI, I can summarize articles.ProQR Therapeutics director Bart Filius purchased 150,000 ordinary shares at $1.72 each, totaling $257,925. This transaction increased his total holding to 300,000 ordinary shares. The information was published via EDGAR on July 21, 2026.
- ProQR Therapeutics director Bart Filius bought 150,000 ordinary shares at USD 1.72 each. * Holding rose to 300,000 ordinary shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-085234), on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here